In this study, survClust analysis of copy number data alone identified aggressive clinical behavior of tumors with CDKN2A deletion in multiple cancer types, and poor survival for a subtype of ovarian cancer carrying aberration on Chromosome 19. This evidence concerns the gene CDKN2A and ovarian cancer.